Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol.
Institute of Applied Health Research, Murray Learning Centre, University of Birmingham, Birmingham.
Br J Gen Pract. 2019 Aug 29;69(686):e612-e620. doi: 10.3399/bjgp19X704585. Print 2019 Sep.
Self-monitoring of blood pressure is common but how telemonitoring with a mobile healthcare (mHealth) solution in the management of hypertension can be implemented by patients and healthcare professionals (HCPs) is currently unclear.
Evaluation of facilitators and barriers to self- and telemonitoring interventions for hypertension within the Telemonitoring and Self-monitoring in Hypertension (TASMINH4) trial.
An embedded process evaluation of the TASMINH4 randomised controlled trial (RCT), in the West Midlands, in UK primary care, conducted between March 2015 and September 2016.
A total of 40 participants comprising 23 patients were randomised to one of two arms: mHealth (self-monitoring by free text/short message service [SMS]) and self-monitoring without mHealth (self-monitoring using paper diaries). There were also15 healthcare professionals (HCPs) and two patient caregivers.
Four key implementation priority areas concerned: acceptability of self- and telemonitoring to patients and HCPs; managing data; communication; and integrating self-monitoring into hypertension management (structured care). Structured home monitoring engaged and empowered patients to self-monitor regardless of the use of mHealth, whereas telemonitoring potentially facilitated more rapid communication between HCPs and patients. Paper-based recording integrated better into current workflows but required additional staff input.
Although telemonitoring by mHealth facilitates easier communication and convenience, the realities of current UK general practice meant that a paper-based approach to self-monitoring could be integrated into existing workflows with greater ease. Self-monitoring should be offered to all patients with hypertension. Telemonitoring appears to give additional benefits to practices over and above self-monitoring but both need to be offered to ensure generalisability.
自我血压监测很常见,但目前尚不清楚患者和医疗保健专业人员 (HCP) 如何通过移动医疗 (mHealth) 解决方案实施远程监测来管理高血压。
评估 Telemonitoring 和 Self-monitoring in Hypertension (TASMINH4) 试验中高血压自我和远程监测干预的促进因素和障碍。
在英国西米德兰兹地区的初级保健中,对 TASMINH4 随机对照试验 (RCT) 进行了嵌入式过程评估,该试验于 2015 年 3 月至 2016 年 9 月进行。
共有 40 名参与者,包括 23 名患者,随机分为两个组:mHealth(通过自由文本/短信服务 [SMS] 进行自我监测)和无 mHealth 的自我监测(使用纸质日记进行自我监测)。还有 15 名医疗保健专业人员 (HCP) 和两名患者护理人员。
四个关键的实施重点领域包括:患者和 HCP 对自我和远程监测的接受程度;管理数据;沟通;以及将自我监测整合到高血压管理(结构化护理)中。结构化家庭监测使患者能够自我监测,无论是否使用 mHealth,都能参与并赋予患者权力,而远程监测则可能促进 HCP 和患者之间更快速的沟通。基于纸张的记录更能融入当前的工作流程,但需要更多的人员投入。
尽管 mHealth 远程监测促进了更轻松的沟通和便利,但英国普通实践的现实情况意味着基于纸张的自我监测方法可以更轻松地整合到现有工作流程中。所有高血压患者都应接受自我监测。远程监测似乎为实践带来了超越自我监测的额外好处,但两者都需要提供,以确保普遍性。